SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

AGHAZADEH TABRIZI, Mojgan
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 14.813
EU - Europa 7.333
AS - Asia 6.669
SA - Sud America 1.154
Continente sconosciuto - Info sul continente non disponibili 184
AF - Africa 164
OC - Oceania 13
Totale 30.330
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 14.482
SG - Singapore 2.316
FI - Finlandia 2.170
DE - Germania 2.069
CN - Cina 1.846
BR - Brasile 909
VN - Vietnam 689
UA - Ucraina 650
HK - Hong Kong 586
RU - Federazione Russa 540
TR - Turchia 516
IT - Italia 499
GB - Regno Unito 466
SE - Svezia 297
FR - Francia 241
CA - Canada 159
IN - India 140
PL - Polonia 120
BD - Bangladesh 115
JP - Giappone 112
AR - Argentina 109
MX - Messico 104
ZA - Sudafrica 67
IQ - Iraq 55
ID - Indonesia 52
BE - Belgio 43
NL - Olanda 43
PK - Pakistan 36
ES - Italia 35
CO - Colombia 34
LT - Lituania 29
EC - Ecuador 28
MA - Marocco 24
UZ - Uzbekistan 24
CZ - Repubblica Ceca 23
AE - Emirati Arabi Uniti 21
CL - Cile 17
SA - Arabia Saudita 17
EG - Egitto 16
MY - Malesia 16
CR - Costa Rica 15
KE - Kenya 15
VE - Venezuela 15
AT - Austria 14
IL - Israele 14
KR - Corea 13
TW - Taiwan 13
AU - Australia 12
PH - Filippine 12
PY - Paraguay 12
JM - Giamaica 11
SK - Slovacchia (Repubblica Slovacca) 11
TN - Tunisia 11
BO - Bolivia 10
NP - Nepal 10
PE - Perù 10
DZ - Algeria 9
UY - Uruguay 9
IE - Irlanda 8
TH - Thailandia 8
AZ - Azerbaigian 7
BH - Bahrain 7
CH - Svizzera 7
EU - Europa 7
RO - Romania 7
AL - Albania 6
BG - Bulgaria 6
IR - Iran 6
KZ - Kazakistan 6
PA - Panama 6
PT - Portogallo 6
GR - Grecia 5
GT - Guatemala 5
LV - Lettonia 5
NI - Nicaragua 5
ET - Etiopia 4
HN - Honduras 4
KG - Kirghizistan 4
LB - Libano 4
MK - Macedonia 4
MN - Mongolia 4
RS - Serbia 4
SV - El Salvador 4
TT - Trinidad e Tobago 4
BA - Bosnia-Erzegovina 3
BY - Bielorussia 3
DO - Repubblica Dominicana 3
HR - Croazia 3
HU - Ungheria 3
JO - Giordania 3
KH - Cambogia 3
KW - Kuwait 3
MD - Moldavia 3
MT - Malta 3
AO - Angola 2
BS - Bahamas 2
CG - Congo 2
CI - Costa d'Avorio 2
OM - Oman 2
PS - Palestinian Territory 2
Totale 30.116
Salva come PNG Salva come JPEG
Città #
Helsinki 1.978
Singapore 1.569
Ashburn 1.386
Woodbridge 1.266
Fairfield 1.204
Dallas 976
San Jose 928
Houston 751
Jacksonville 699
Ann Arbor 684
Chandler 574
Santa Clara 571
Beijing 566
Hong Kong 564
Seattle 510
Wilmington 497
Cambridge 394
Council Bluffs 309
Los Angeles 227
Ho Chi Minh City 224
Izmir 221
Nanjing 186
Munich 176
New York 168
Ferrara 154
Hanoi 150
Princeton 147
Boardman 145
San Diego 112
Lauterbourg 110
Tokyo 109
Milan 104
Warsaw 104
Shanghai 99
São Paulo 94
London 75
Bremen 74
Hefei 65
Shenyang 61
Nanchang 60
Orem 60
Mexico City 57
Turku 56
Tianjin 50
Changsha 49
Chicago 48
Montreal 47
Frankfurt am Main 44
Hebei 44
Toronto 44
San Mateo 43
Brooklyn 42
Atlanta 40
Phoenix 39
Brussels 38
Falkenstein 38
Jiaxing 38
Johannesburg 37
Buffalo 34
Denver 34
Haiphong 33
Chennai 32
Moscow 30
Philadelphia 30
Dong Ket 29
Falls Church 29
Stockholm 29
Dearborn 28
Rio de Janeiro 28
Baghdad 27
Jinan 27
San Francisco 27
Da Nang 25
Guangzhou 25
Redwood City 25
Poplar 24
Amsterdam 23
Zhengzhou 23
Boston 22
Brasília 22
Mountain View 22
Addison 21
The Dalles 21
Curitiba 20
Kunming 20
Ankara 19
Belo Horizonte 19
Mumbai 19
Tashkent 18
Jakarta 17
Manchester 16
Brno 15
Columbus 15
Hangzhou 15
Orange 15
Washington 15
Auburn Hills 14
Bexley 14
Charlotte 14
Indiana 14
Totale 20.054
Salva come PNG Salva come JPEG
Nome #
1,3-Dipropyl-8-(1-phenylacetamide-1H-pyrazol-3-yl)-xanthine derivatives as highly potent and selective human A2B adenosine receptor antagonists 3.125
Medicinal Chemistry, Pharmacology, and Clinical Implications of TRPV1 Receptor Antagonists 349
Handbook of Cannabis and Related Pathologies 340
A3 Adenosine Receptors as Modulators of Inflammation: From Medicinal Chemistry to Therapy 333
A glance at adenosine receptors: Novel target for antitumor therapy 322
Synthesis and Structure Activity Relationship Investigation of Triazolo[1,5-a]pyrimidines as CB2 Cannabinoid Receptor Inverse Agonists 317
A3 adenosine receptor antagonists: History and future perspectives 300
The A3 adenosine receptor: history and perspectives 294
A [3+2] nitrile oxide intermolecular cycloaddition approach to 4,5-dihydro-3(2H)-furanone and 3(2H)-furanone ring systems: application to the formal synthesis of (±)-ascofuranone and geiparvarin. 287
Design, synthesis, and biological evaluation of novel 2-((2-(4-(substituted)phenylpiperazin-1-yl)ethyl)amino)-5'-N-ethylcarboxamidoadenosines as potent and selective agonists of the A2A adenosine receptor 286
7-Substituted-pyrrolo[3,2-d]pyrimidine-2,4-dione derivatives as antagonists of the transient receptor potential ankyrin 1 (TRPA1) channel: A promising approach for treating pain and inflammation 274
Design and Synthesis of Potent in Vitro and in Vivo Anticancer Agents Based on 1-(3’,4’,5’-Trimethoxyphenyl)-2-Aryl-1H-Imidazole 273
Synthesis and biological evaluation of 2-and 3-aminobenzo[b]thiophene derivatives as antimitotic agents and inhibitors of tubulin polymerization 272
A synthetic approach for the preparation of rigid analogs of 1,3-dipropyl-7-methyl-8-aryl/heteroarylstyryl xanthines 270
Adenosine receptors and human melanoma 264
Design, synthesis, DNA binding, and biological evaluation of water-soluble hybrid molecules containing two pyrazole analogues of the alkylating cyclopropylpyrroloindole (CPI) subunit of the antitumor agent CC-1065 and polypyrrole minor groove binders 263
Allosteric modulators for the A1-adenosine receptor 263
7-Oxo-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxamides as Selective CB2 Cannabinoid Receptor Ligands: Structural Investigations around a Novel Class of Full Agonists 262
[H-3]-MRE 2029-F20, a selective antagonist radioligand for the human A(2B) adenosine receptors 261
N-6-[(Hetero)aryl/(cyclo)alkyl-carbamoyi-methoxy-phenyl]-(2chloro)-5 '-N-ethylearboxamido-adenosines: The first example of adenosine-related structures with potent agonist activity at the human A(2B) adenosine receptor 254
Design, synthesis and in vitro cytotoxicity of a cis-dichloroplatinum(II) complex linked to the minor groove binder stallimycin 252
Pyrazolo [4,3-e][1,2,4]triazolo[1,5-c]pyrimidine template: Organic and medicinal chemistry approach 251
New 2-heterocyclyl-imidazo[2,1- i ]purin-5-one derivatives as potent and selective human A 3 adenosine receptor antagonists 249
Allosteric enhancers for A(1) adenosine receptor 248
DNA minor groove binders as potential antitumor and antimicrobial agents 248
New heterocyclic ligands for the adenosine receptors P1 and for the ATP receptors P2. 243
Blockade of A2A receptors plus L-DOPA after nigrostriatal lesion results in GAD67 mRNA changes different from L-DOPA alone in the rat globus pallidus and substantia nigra reticulata 242
One-pot reaction to obtain N,N'-disubstituted guanidines of pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine scaffold as human A3 adenosine receptor antagonists 236
Synthesis and biological effects of a new series of 2-amino-3-benzoylthiophenes as allosteric enhancers of A1-adenosine receptor 235
Adenosine Receptor Antagonists: Translating Medicinal Chemistry and Pharmacology into Clinical Utility 232
Novel 8-heterocyclyl xanthine derivatives in drug development - An update 232
Pyrazole phenylcyclohexylcarbamates as inhibitors of human fatty acid amide hydrolases (FAAH) 231
Synthesis and preliminary biological evaluation of new anti-tubulin agents containing different benzoheterocycles 230
Hybrid molecules between distamycin A and active moieties of antitumor agents 229
From tyrosine to glycine: Synthesis and biological activity of potent antagonists of the purinergic P2X(7) receptor 228
Synthesis of a new series of pyrazolo[1,5-a]pyrimidines structurally related to zaleplon 228
Hybrid molecules based on distamycin A as potential antitumor agents 228
Geiparvarin analogs. 2. Synthesis and cytostatic activity of 5-(4-arylbutadienyl)-3(2H)-furanones and of N-substituted 3-(4-oxo-2-furanyl)-2-buten-2-yl carbamates. 226
Biological effects of novel 2-amino-3-naphthoylthiophenes as allosteric enhancers of the A1 adenosine receptors 225
Synthesis and biological evaluation of 2-(3 ',4 ',5 '-trimethoxybenzoyl)-3-amino 5-aryl thiophenes as a new class of tubulin inhibitors 222
New heterocyclic ligands for the adenosine receptors P1 and for the ATP receptors P2 221
Structure-activity relationship studies of a new series of imidazo[2,1-f] purinones as potent and selective A3 adenosine receptor antagonists 220
Design, synthesis, and biological evaluation of new 8-heterocyclic xanthine derivatives as highly potent and selective human A(2B) adenosine receptor antagonists 219
Pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidines and linked Heterocycles as template for the adenosine receptor antagonism: Medicinal chemistry approach and sar considerations 218
Microwave-assisted synthesis of thieno[2,3-c]pyridine derivatives as a new series of allosteric enhancers at the adenosine A(1) receptor 218
Recent improvements in the development of A2B adenosine receptor agonists 217
Structure-activity relationships around the KN-62, a potent antagonist of the P2X(7)receptor 215
Discovery and Optimization of a Series of 2-Aryl-4-Amino-5-(3 ',4 ',5 '-trimethoxybenzoyl)Thiazoles as Novel Anticancer Agents 215
Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson's disease 215
Synthesis and Biological Evaluation of Novel Allosteric Enhancers of the A1 Adenosine Receptor Based on 2-Amino-3-(4’-Chlorobenzoyl)-4-Substituted-5-Arylethynyl Thiophene 214
Design, synthesis and growth inhibition activity of bis-epoxyethyl derivatives of stallimycin modified on the amidino moiety 213
Modulation of metalloproteinase-9 in U87MG glioblastoma cells by A3 adenosine receptors 213
Synthesis of conformationally constrained analogues of KN62, a potent antagonist of the P2X7-receptor 212
A structural study of new potent and selective antagonists to the A(2B) adenosine receptor 210
Water-Soluble Pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidines as Human A3 Adenosine Receptor Antagonists 208
Medicinal chemistry, pharmacology, and potential therapeutic benefits of cannabinoid CB2receptor agonists 208
Synthesis and biological evaluation of 2-amino-3-(3',4',5'-trimethoxyphenylsulfonyl)-5-aryl thiophenes as a new class of antitubulin agents 207
Recent developments in the field of adenosine receptor ligands. 206
Recent improvements in the development of A2B adenosine receptor agonists 206
Pharmacological characterization of novel adenosine ligands in recombinant and native human A2B receptors 206
New pyrrolo[2,1-f]purine-2,4-dione and imidazo[2,1-f]purine-2,4-dione derivatives as potent and selective human A(3) adenosine receptor antagonists 204
Geiparvarin Analogs. 3. Synthesis and cytostatic activity of 3(2H)-furanone and 4,5-dihydro-3(2H)-furanone congeners of geiparvarin, containing a geraniol-like fragment in the side chain 202
Synthesis and Biological Evaluation of 1-Methyl-2-(3’,4’,5’-Trimethoxybenzoyl)-3-Amino Indoles as a New Class of Antimitotic Agents and Tubulin Inhibitors 201
Recent developments in the field of A(2A) and A(3) adenosine receptor antagonists 199
Pyrazolotriazolopyrimidine derivatives sensitize melanoma cells to the chemiotherapic drugs: taxol and vindesine. 198
Recent developments in A2B adenosine receptor ligands 198
Synthesis and biological evaluation of 2-amino-3-(4-chlorobenzoyl)-4-[(4- arylpiperazin-1-yl)methyl]-5-substituted-thiophenes. Effect of the 5-modification on allosteric enhancer activity at the A1 adenosine receptor 198
New 2-arylpyrazolo[4,3-c]quinoline derivatives as potent and selective human A(3) adenosine receptor antagonists 197
Microwave-assisted synthesis of substituted 2,4-diarylthiazoles and their evaluation as anticancer agents 195
New strategies for the synthesis of A(3) adenosine receptor antagonists 195
Hybrid molecules containing benzo[4,5]imidazo[1,2-d][1,2,4]thiadiazole and alpha-bromoacryloyl moieties as potent apoptosis inducers on human myeloid leukaemia cells 193
Synthesis, radiolabeling, and preliminary biological evaluation of [H-3]-1-[(S)-N,O-bis-(isoquinolinesulfonyl)-N-methyl-tyrosyl]-4-(o-tolyl )-piperazine, a potent antagonist radioligand for the P2X(7) receptor 191
MODULATION OF MMP-9 IN U87MG GLIOBLASTOMA CELLS BY A3 ADENOSINE RECEPTORS 190
New synthesis of diazepino[3,2,1-ij]quinoline and pyrido[1,2,3-de] quinoxalines via addition-elimination followed by cycloacylation 186
New 2-arylpyrazolo[4,3-c]quinoline derivates as potent and selective human A3 adenosine receptor antagonists 186
Preparation of substituted purinylpyrazolylacetamides as adenosine A2B receptor antagonists. 185
Cytotoxic drugs regulate VEGF and IL-8 expression in human melanoma cells by A2A and A3 adenosine receptors. 184
Blockade of globus pallidus adenosine A2A receptors displays antiparkinsonian activity in 6-hydroxydopamine-lesioned rats treated with D 1 or D2 dopamine receptor agonists 183
Design, synthesis, and biological evaluation of C-9- and C-2-substituted pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c] pyrimidines as new A(2A) and A(3) adenosine receptors antagonists 182
Pharmacological characterization of novel adenosine ligands in recombinant and native human A2B receptors 179
Preparation of fused purine derivatives as adenosine A3 receptor modulators. 178
Synthesis and biological evaluation of novel N-6-[4-(substituted) sulfonamidophenylcarbamoyl]adenosine-5 '-uronamides as A(3) adenosine receptor agonists 177
Concise Synthesis and Biological Evaluation of 2-Aroyl-5-Amino Benzo[b]thiophene Derivatives As a Novel Class of Potent Antimitotic Agents 175
Recent improvements in the field of A(3) adenosine receptor ligands 173
Pharmacological characterization of novel adenosine ligands in recombinant and native human A2B receptors 172
Preparation of fused purine derivatives as adenosine A3 receptor modulators. 171
Discovery of 1,5-Diphenylpyrazole-3-Carboxamide Derivatives as Potent, Reversible, and Selective Monoacylglycerol Lipase (MAGL) Inhibitors 171
Recent developments in the field of adenosine receptor ligands 170
Synthesis and biological evaluation of 2-substituted-4-(3 ',4 ',5 '-trimethoxyphenyl)-5-aryl thiazoles as anticancer agents 170
Involvement of globus pallidus in the antiparkinsonian effects of adenosine A2A receptor antagonists 169
Allosteric enhancers of A1 adenosine receptors: State of the art and new horizons for drug development 168
Modulation of MMP-9 in U87MG glioblastoma cells by A3 adenosine receptors. 168
Structure-activity relationships of 2-amino-3-aroyl-4-[(4-arylpiperazin-1- yl)methyl]thiophenes. Part 2: Probing the influence of diverse substituents at the phenyl of the arylpiperazine moiety on allosteric enhancer activity at the A 1 adenosine receptor 165
Dopamine and adenosine receptor interaction as basis for the treatment of Parkinson's disease 165
Antinociceptive effects of the selective CB2 agonist MT178 in inflammatory and chronic rodent pain models. 163
Ligands for A(2B) adenosine receptor subtype 162
Design, synthesis and biological evaluation of hybrid molecules containing conjugated styryl ketone and α-bromoacryloyl moieties 161
New pyrrolo [2,1-f] purine-2,4-dione and Imidazo[2,1-f]purine-2,4-dione derivates as potent and selective human A3 adenosine receptor antagonists 160
Role of strong intramolecular N-H...N hydrogen bonds in determining the conformation of adenosine-receptors antagonists 157
Pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine ligands, new tools to characterize A(3) adenosine receptors in human tumor cell lines 155
Totale 24.781
Salva come PNG Salva come JPEG
Categoria #
all - tutte 113.164
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 2.746
Totale 115.910
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.344 0 0 147 53 98 78 79 53 57 118 150 511
2022/20231.389 142 82 26 183 291 209 58 109 171 10 67 41
2023/2024752 67 94 43 28 56 111 38 74 13 10 11 207
2024/20253.165 65 101 246 128 370 336 120 189 405 315 474 416
2025/202611.365 906 586 1.351 1.112 1.268 692 1.001 454 2.561 1.042 276 116
2026/20271.043 277 457 309 0 0 0 0 0 0 0 0 0
Totale 30.330